Reuters logo
BRIEF-Coherus Biosciences announces positive topline 24-week treatment Phase 3 results for CHS-1420 in patients with Psoriasis
January 10, 2017 / 2:22 PM / a year ago

BRIEF-Coherus Biosciences announces positive topline 24-week treatment Phase 3 results for CHS-1420 in patients with Psoriasis

Jan 10 (Reuters) - Coherus Biosciences Inc

* Coherus Biosciences announces positive topline 24-week treatment phase three results for CHS-1420 (HUMIRA biosimilar candidate) in patients with Psoriasis

* Coherus Biosciences Inc - Study met its primary endpoint

* Currently anticipate filing biologic license application (BLA) submission in first half of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below